


CLAIMS

What is claimed is:


1. 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide
5 of the formula I



Handwritten annotations show mass spectra fragmentation paths:
546 → 329
514 → 183 → 277 → 345
351

or its physiologically tolerable salts.

- 10 2. 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide
as claimed in claim 1, *per se*.
- 15 3. A method for the therapy or prophylaxis of cardiac arrhythmias, of
supraventricular arrhythmias, of atrial fibrillation or atrial flutters comprising the
administration of an efficacious amount of 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-
methoxypyridin-3-yl)-propyl]benzamide or a physiologically tolerable salt thereof as
claimed in claim 1.
- 20 4. A pharmaceutical preparation for human or veterinary use comprising an
efficacious amount of 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-
yl)propyl]benzamide of the formula I or a physiologically tolerable salt thereof as
claimed in claim 1, together with pharmaceutically acceptable vehicles or additives.
- 25 5. The pharmaceutical preparation of claim 4 further comprising one or more
other pharmacologically active compounds.

NH₂

6. 1(R)-(6-Methoxypyridin-3-yl)propylamine.



7. A process for the preparation of 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide or its physiologically tolerable salts, the
5 process comprising the use of 1(R)-(6-methoxypyridin-3-yl)propylamine as an intermediate.

no steps